Vol. 21/No. 21

The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly targeted therapies in oncology.

Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma.

Patients on active therapy during the coronavirus disease 2019 pandemic, as well as oncology care providers, have increased levels of perceived and posttraumatic stress, according to preliminary data from the COVIPACT study.

TP53-targeted treatment options represent an unmet need for patients with myelodysplastic syndromes and acute myeloid leukemia.

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

Practices and cancer centers in randomly selected zip codes will be required to participate in the new radiation oncology Model, which is expected to cover approximately 30% of eligible Medicare fee-for-service care episodes.

Investigators are testing tipifarnib, a novel drug that inhibits a critical enzyme needed for HRAS activation, in patients with head and neck squamous cell carcinoma whose tumors harbor the mutation.

Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.

A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.

Despite solid evidence that human papillomavirus vaccination is remarkably effective in preventing persistent infection by HPV types that are known to be responsible for more than 70% to 80% of cervical cancer cases worldwide, this strategy’s utility in substantially reducing the subsequent development of the malignancy itself remained an open question.